Enanta Pharmaceuticals

1. EPS-3903 IND filing2H 2026EPS-3903 IND filing, 2H 2026, notable
2. MRGPRX2 Inhibitor corporate update2H 2026MRGPRX2 Inhibitor corporate update, 2H 2026, routine
3. MRGPRX2 program corporate update2H 2026MRGPRX2 program corporate update, 2H 2026, routine
4. Enanta v. Pfizer UPC corporatemid-to-late 2026Enanta v. Pfizer UPC corporate, mid-to-late 2026, routine
5. EDP-978 Ph1 topline4Q 2026EDP-978 Ph1 topline, 4Q 2026, material
6. RESOLVE Ph2b start4Q 2026RESOLVE Ph2b start, 4Q 2026, notable
7. Zelicapavir Ph3 start4Q 2026Zelicapavir Ph3 start, 4Q 2026, routine
8. Fiscal Q4 earnings financingNov 16, 2026Fiscal Q4 earnings financing, Nov 16, 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.